Abstract:Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).

Surviving the Storm: The Role of Poly‐ and Depolyploidization in Tissues and Tumors

Nondiploid Cancer Cells: Stress, Tolerance and Therapeutic Inspirations.

[Polyploidy as an outcome of anticancer therapies and a contributing cause of their lack of efficacy]

Polyploidy in Cancer: causal mechanisms, cancer-specific consequences, and emerging treatments

The antagonistic relationship between apoptosis and polyploidy in development and cancer

Polyploidy mitigates the impact of DNA damage while simultaneously bearing its burden

Computational Biology Helps Understand How Polyploid Giant Cancer Cells Drive Tumor Success

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

Poly-aneuploid cancer cells promote evolvability, generating lethal cancer

Polyploid Cancer Cell Models in Drosophila

Polyploid giant cancer cells: origin, possible pathways of formation, characteristics, and mechanisms of regulation

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy

Tetraploidy as a metastable state towards malignant cell transformation within a systemic approach of cancer development

Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidization

Polyploid cancer cells reveal signatures of chemotherapy resistance

The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells

Aurora B inhibition promotes a hyper-polyploid state and continued endomitotic cycles in RB and p53 defective cells

Cancer Cells Enter an Adaptive Persistence to Survive Radiotherapy and Repopulate Tumor

Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies

Single-cell morphological and transcriptome analysis unveil inhibitors of polyploid giant breast cancer cells in vitro